Brazil's health authority has given the green light to a new generation of GLP-1 obesity drugs. Here is what patients need to know about how these medications work.
Brazil's health authority ANVISA has recently approved new medications for obesity treatment, expanding the options available to patients who need medical support to manage their weight. These drugs belong to a class known as GLP-1 receptor agonists, and they work differently from older weight loss medications that relied on appetite suppression or fat blocking. Understanding how these new treatments function can help patients have more informed conversations with their doctors.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are synthetic versions of a hormone the human body produces naturally in the intestines. This hormone, called glucagon-like peptide-1, plays a key role in regulating blood sugar and appetite. When used as medication, GLP-1 agonists mimic these natural effects at a much stronger level, helping people eat less without feeling deprived.
The first major GLP-1 medication for diabetes was approved years ago, but researchers discovered that patients taking these drugs for blood sugar control also lost significant amounts of weight. Drug manufacturers then developed higher-dose formulations specifically designed for weight management, leading to a new wave of obesity treatments reaching the market.
How These Medications Work in the Body
GLP-1 obesity medications work through two main pathways in the body. First, they act on specific areas of the brain that control hunger and satiety, making people feel fuller faster and for longer after eating. Second, they slow down the rate at which the stomach empties its contents, extending the feeling of fullness after meals.
These combined effects typically lead to a natural reduction in daily calorie intake without the need for constant willpower. Patients often report that the constant food noise that used to occupy their minds becomes much quieter, which many describe as a surprising but welcome change.
Unlike stimulants that were commonly prescribed for weight loss in the past, GLP-1 medications do not increase heart rate or cause jitters. They also do not work by blocking fat absorption, which means nutritional deficiencies are not a typical concern with this class of drugs.
Medications With ANVISA Approval for Obesity
ANVISA has approved several GLP-1 medications for chronic weight management in Brazil. Semaglutide, sold under the brand name Wegovy for obesity treatment, was approved by the Brazilian health authority after showing strong results in clinical trials. This weekly injectable medication has become one of the most talked-about options in the country.
Liraglutide, marketed as Saxenda for obesity, is another GLP-1 agonist with ANVISA approval for weight management. It requires daily injections but has been available longer, giving physicians more experience with its use in Brazilian patients.
Tirzepatide, approved by ANVISA for type 2 diabetes under the brand Mounjaro, has also attracted attention for its weight loss effects. Clinical data has shown substantial weight reduction in patients using this medication.
What Patients Should Know Before Starting
Anyone considering GLP-1 obesity medication should understand that these are prescription-only treatments requiring medical supervision. A healthcare provider will evaluate whether the medication is appropriate based on the patient's health history, current medications, and weight loss goals.
Side effects are most common when first starting treatment or when doses are increased. Nausea, diarrhea, and constipation are frequently reported, especially during the initial weeks. These symptoms tend to diminish as the body adjusts, and doctors usually start patients on lower doses before gradually increasing to the therapeutic level.
Cost is a significant factor for many patients. GLP-1 obesity medications can be expensive, and Brazilian public health system SUS coverage for these treatments remains limited. Patients should check with their health insurance providers about coverage options before starting therapy.
These medications are intended for use alongside sustainable lifestyle changes, not as standalone solutions. Nutrition habits and physical activity still matter for long-term success, and stopping the medication may lead to weight regain if habits have not been established.
Looking Ahead
The approval of GLP-1 obesity medications by ANVISA represents a shift in how Brazil approaches weight management. These treatments offer a different mechanism of action compared to older options, and many patients and doctors are paying close attention to the results seen in clinical practice.
Research on GLP-1 medications continues to expand, with studies exploring their effects beyond weight loss. Some researchers are investigating potential benefits for heart health and metabolic conditions, though much of this work is still ongoing.
Staying informed about how these medications work helps patients make better decisions and have more productive conversations with their healthcare teams. Following trusted sources like OzemNews can make it easier to keep up with developments in this rapidly changing area of obesity treatment.
FAQ
How do GLP-1 obesity medications work in the body?
They mimic the natural GLP-1 hormone to reduce appetite and slow stomach emptying, helping people feel fuller longer and eat less without constant effort.
How long does it take to see results with these medications?
Many patients notice appetite changes within the first few weeks. Meaningful weight loss typically becomes visible over several months of consistent use combined with lifestyle modifications.
What are the most common side effects?
Nausea, diarrhea, and constipation are the most frequently reported side effects, especially during dose increases. These usually improve over time as the body adjusts to the medication.
Are these medications covered by public health insurance in Brazil?
Coverage through SUS is currently limited. Patients should check with their insurance providers about specific coverage options, as policies vary widely between plans.
Do I still need to follow a diet and exercise plan while using GLP-1 medications?
Yes. These medications work best when combined with sustainable lifestyle changes. Stopping treatment without establishing healthy habits may result in regaining the weight lost.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
